|Articles|October 1, 2003
Risks of TNF-α Blockers
Montreal - Drugs that block tumor necrosis factor alpha are showing great promise for the treatment of moderate to severe psoriasis, a condition that causes sufferers a good deal of misery and that can be frustratingly resistant to many treatments. However, the high potency comes with a tradeoff. Research indicates that blocking TNF-a may place patients at a higher risk for serious infections, notably tuberculosis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5













